Antibody titer after anti-idiotype rabies vaccination with nano-chitosan adjuvant
- Authors: Paryati S.P.1, Ramadhanti S.1, Hasan K.1
-
Affiliations:
- General Achmad Yani University
- Issue: Vol 14, No 4 (2024)
- Pages: 788-794
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/268712
- DOI: https://doi.org/10.15789/2220-7619-ATA-17564
- ID: 268712
Cite item
Full Text
Abstract
Background. The rabies virus neutralizing antibodies titers is a public health problem in the world, including Indonesia. Rabies is zoonotic and causes death in humans with a case fatality rate of 100%. Anti-idiotype antibody (Ab2) from chicken immunoglobulin (IgY) can be a substitute antigen for the rabies virus. This research aims to study the potential of rabies vaccine based on anti-idiotype antibody (Ab2) with nano-chitosan as an adjuvant. Materials and methods. The production of Ab2 is derived from purified and characterized chicken immunoglobulins. Nano-chitosan is made from chitosan from shrimp shell waste. Vaccination tests were carried out on rats compared with commercial vaccines as a positive control and physiological solutions as a negative control. The characterization results of IgY Ab2 were IgY rabies with BM ~180 kDa, heavy chains (BM ~60 kDa), and light chains (BM ~30 kDa) of IgY. Nano-chitosan is less than 100 nm in size, can dissolve well, and does not cause side effects in experimental animals. Results. The vaccine formula uses a concentration of 0.5%, where the ratio of nano-chitosan and Ab2 is 1:1. The Ab2 concentration used was about 1000 units per mL of the Ab2 suspension. Conclusion. This study concludes that anti-idiotype antibodies dissolved in nano-chitosan adjuvant can induce the formation of antibodies with titers that are not statistically different from the antibody titers induced by commercial rabies vaccines. Nano-chitosan has a potential vaccine adjuvant candidate, safe to use, and can enhance the immunogenicity of an antigen applied subcutaneously. According to the results of this study, it is recommended that post-vaccination antibody titers be measured regularly: for example, every one week for six weeks after vaccination. This measurement determines the time of the peak of the antibody titer so that the time for revaccination can be determined.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Sayu Putu Yuni Paryati
General Achmad Yani University
Author for correspondence.
Email: yunisayu@yahoo.com
Doctor of Veterinary Medicine, Lecturer at the Faculty of Medicine
Indonesia, CimahiS. Ramadhanti
General Achmad Yani University
Email: yunisayu@yahoo.com
Doctor of Medicine, Graduate of the Faculty of Medicine
Indonesia, CimahiK. Hasan
General Achmad Yani University
Email: yunisayu@yahoo.com
PhD of Protein Engineering, Lecturer at the Department of Biochemistry, Faculty of Medicine
Indonesia, CimahiReferences
- Abbas A.K., Lichtman A.H., Pillai S. Basic immunology: functions and disorders of the immune system. St. Louis, Missouri: Elsevier Science Pub Co, 2016. URL: https://archive.org/details/basicimmunologyf0000abba_w9e9
- American Veterinary Medical Association. AVMA Guidelines for the Euthanasia of Animals. 2013. URL: https://www.avma.org/resources-tools/avma-policies/avma-guidelines-euthanasia-animals
- Amri Y., Fajri R., Novitasari P., Zulfajri M. The effect of tripolyphosphate (tpp) volumes on the synthesis of chitosan nanoparticles using ionic gelation method. Proceedings of the 2nd International Conference on Science, Technology, and Modern Society (ICSTMS 2020), 2021, vol. 576, pp. 213–216. doi: 10.2991/assehr.k.210909.048
- National Research Council. Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, DC: The National Academies Press, 2011. doi: 10.17226/12910
- Data and Information Center of the Ministry of Health of the Republic of Indonesia. Rabies situation and analysis in 2014. Jakarta: Ministry of Health of the Republic of Indonesia, 2014. URL: https://p2pm.kemkes.go.id/storage/publikasi/media/file_1619049298.pdf
- De Jong J.C., Palache A.M., Beyer W.E.P., Rimmelzwaan G.F., Boon A.C.M., Osterhaus A.D.M.E. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. (Basel), 2003, vol. 115, pp. 63–73.
- Doan C.T., Tran T.N., Nguyen V.B., Nguyen A.D., Wang S.-L. Production of a thermostable chitosanase from shrimp heads via Paenibacillus mucilaginosus TKU032 conversion and its application in the preparation of bioactive chitosan oligosaccharides chien. Mar. Drugs, 2019, vol. 17, no. 4: 217. doi: 10.3390/md17040217
- Dzung N.A. Chitosan and chitosan derivatives as potential adjuvants for influenza vaccine. In: Chitin and chitosan derivatives: Advances in drug discovery and developments. Ed. Kim S.K. Boca Raton: CRC Taylors & Francis, 2014, pp. 481–492. doi: 10.1201/b15636
- European Commission: Directorate-General for Environment. Caring for animals aiming for better science — Directive 2010/63/EU on protection of animals used for scientific purposes: Animal welfare bodies and national committees, 2018. URL: https://data.europa.eu/doi/10.2779/059998
- Fisher C.R., Schnell M.J. New developments in rabies vaccination. Rev. Sci. Tech., 2018, vol. 37, no. 2, pp. 657–672. doi: 10.20506/rst.37.2.2831
- Holley T., Bowe G., Campia I., Belz S., Berggren E., Janusch Roi A., Wittwehr C., Whelan M. European Union Reference Laboratory for Alternatives to Animal Testing: Dataset Collection, 2017. URL: https://joint-research-centre.ec.europa.eu/eu-reference-laboratory-alternatives-animal-testing-eurl-ecvam_en
- Hunter R.L. Overview of vaccine adjuvants: present and future. Vaccine, 2002, vol. 20, no. 3, pp. 7–12. doi: 10.1016/s0264-410x(02)00164-0
- Li X., Dong W., Nalin A.P., Wang Y., Pan P., Xu B. The natural product chitosan enhances the anti-tumor activity of natural killer cells by activating dendritic cells. Oncoimmunology, 2018, vol. 7, no. 6: e1431085. doi: 10.1080/2162402X.2018.1431085
- Mursal I.L.P., Warsito A.M.P., Ariyanti D.K., Susanti E., Irma R. Use of chitosan nanoparticles as new drug delivery. Journal of Pharmaceutical and Sciences, 2023, vol. 6, no. 2, pp. 804–809. doi: 10.36490/journal-jps.com.v6i2.136
- Paryati S.P.Y., Hasan K., Nawangsih E.N., Inayati I., Rakhmat. Purification and characterization of rabies anti-idiotype antibodies isolated purification and characterization of rabies anti-idiotype antibodies isolated from chicken egg yolks. Int. J. Pharm. Res., 2020, vol. 12, no. 3, pp. 1629–1634. doi: 10.31838/ijpr/2020.12.03.223
- Paryati S.P.Y., Nawangsih E.N., Inayati I., Rakhmat. Preparation of anti-idiotype antibody as diagnostic kit in rabies serological test. 4th Syiah Kuala University Annual International Conference 2014; Banda Aceh, Indonesia, 2014, pp. 138–143. URL: https://www.neliti.com/publications/174146/preparation-of-anti-idiotype-antibody-as-diagnostic-kit-in-rabies-serological-te
- Paryati S.P.Y., Wibawan I.W.T., Soejoedono R.D., Pasaribu F.H. Chicken immunoglobulin as an anti-idiotype antibody against rabies (Imunoglobulin ayam sebagai antibodi anti-idiotipe terhadap rabies). J. Vet., 2006, vol. 7, no. 3, pp. 92–103.
- Pasquale A.D., Preiss S., Silva F.T.D., Garçon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel), 2015, vol. 3, no. 2, pp. 320–343. doi: 10.3390/vaccines3020320
- Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell. Biol., 2004, vol. 82, no. 5, pp. 488–496. doi: 10.1111/j.0818-9641.2004.01272.x
- Roitt I.M., Brostoff J., Male D.K. Immunology 3rd ed. London: Mosby-Year Book Europe Ltd. 2003. URL: https://books.google.co.id/books/about/Immunology.html?id=a6tpAAAAMAAJ&redir_esc=y
- Roitt I.M., Delves P.J. Roitt‘s essential immunology. UK: Blackwell Science Ltd. 2001. URL: https://dl.mehrsys.ir/pdf-books/Roitt_s%20Essential%20Immunology%20Thirteenth%20Edition(www.myuptodate.com).pdf
- Saha A., Chatterjee S.K., Foon K.A., Primus F.J., Sreedharan S., Mohanty K. Dendritic cells pulsed with an anti-idiotype antibody mimicking Carcinoembryonic Antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res., 2004, vol. 64, no. 14, pp. 4995–5003. doi: 10.1158/0008-5472.CAN-04-0626
- Toovey S. Preventing rabies with the Verorab vaccine: 1985–2005 Twenty years of clinical experience. Travel Med. Infect. Dis., 2007, vol. 5, no. 6, pp. 327–348. doi: 10.1016/j.tmaid.2007.07.004.
- WHO. Rabies vaccines. 2002. URL: https://www.who.int/publications/i/item/who-wer7714
- WHO. Rabies. 2024. URL: https://www.who.int/news-room/fact-sheets/detail/rabies
- WHO. Rabies outbreak response: Accelerating a One Health approach in East NusaTenggara. 2023. URL: https://www.who.int/indonesia/news/detail/18-10-2023-rabies-outbreak-response--accelerating-a-one-health-approach-in-east-nusa-tenggara
- Zhou E.M., Fischer M.M.D., Rector E.S., Sehon A.H., Kisil F.T. A murine monoclonal anti-idiotypic antibody detects a common idiotope on human, mouse and rabbit antibodies to allergen lol p IV. Scand. J. Immunol., 1991, vol. 34, pp. 307–316. doi: 10.1111/j.1365–3083.1991.tb01551.x
Supplementary files
